CONMED's ROE is deemed 'sub-optimal'. The business isn't thrilling as it uses high debt to boost sub-par returns. Theoretically, greater ROE could improve through leverage, but higher debt presents greater risk.
CONMED's stock appears overpriced when gauged against the industry average PE ratio. Despite its positive outlook being factored into its valuation, the elevated price could present a risk to potential sellers and isn't the optimum entry point for potential investors.
CONMED's move to profitability is typically seen as a good sign but investor sentiment may be changing due to recent share price drop. The company exhibits two cautionary signs for investors.
wooper OP : FYI is just getting started will run all day